Heparanase induces Signal Transducer and Activator of Transcription (STAT) protein phosphorylation: Preclinical and clinical significance in head and neck cancer

Journal of Biological Chemistry

Volumn 287, Issue 9, 2012, Pages 6668-6678

  Cohen Kaplan, Victoria ^a   Jrbashyan, Jenny ^b   Yanir, Yoav ^b   Naroditsky, Inna ^c   Ben Izhak, Ofer ^c   Ilan, Neta ^a   Doweck, Ilana ^b   Vlodavsky, Israel ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

^c Rambam Health Care Campus ^*  (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

C-TERMINAL DOMAINS; CELLULAR LOCALIZATION; ENZYMATIC ACTIVITIES; HEAD AND NECK; HEAD-AND-NECK CANCER; HEPARANASE; IMMUNE SYSTEMS; LYMPH NODE; METASTATIC TUMORS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCERS; SIGNALING MOLECULES; TRANSFECTED CELLS; TUMOR SIZE;

CYTOLOGY; DISEASES; TRANSCRIPTION; TUMORS;

PHOSPHORYLATION;

EPIDERMAL GROWTH FACTOR RECEPTOR; HEPARANASE; SMALL INTERFERING RNA; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; ENZYME ACTIVITY; ENZYME INDUCTION; GENETIC TRANSFECTION; HEAD AND NECK CANCER; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TUMOR VOLUME;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CELLS, CULTURED; DISEASE PROGRESSION; FEMALE; FIBROBLASTS; GLUCURONIDASE; HEAD AND NECK NEOPLASMS; HUMANS; LARYNGEAL NEOPLASMS; MALE; MICE; MULTIPLE MYELOMA; NOSE NEOPLASMS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TONGUE NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84857477759     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.271346     Document Type: Article

References (56)

1. Parish, C. R., Freeman, C., and Hulett, M. D. (2001) Heparanase: a key enzyme involved in cell invasion. Biochim. Biophys. Acta 1471, M99-108
2. Vlodavsky, I., and Friedmann, Y. (2001) Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 108, 341-347 (Pubitemid 32730777)
3. Dempsey, L. A., Brunn, G. J., and Platt, J. L. (2000) Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem. Sci. 25, 349-351 (Pubitemid 30497237)
4. Ilan, N., Elkin, M., and Vlodavsky, I. (2006) Regulation, function, and clinical significance of heparanase in cancer metastasis and angiogenesis. Int. J. Biochem. Cell Biol. 38, 2018-2039 (Pubitemid 44397619)
5. Sanderson, R. D., Yang, Y., Kelly, T., MacLeod, V., Dai, Y., and Theus, A. (2005) Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J. Cell. Biochem. 96, 897-905 (Pubitemid 41688716)
6. Shafat, I., Bem-Arush, M. W., Issakov, J., Meller, I., Naroditsky, I., Tortoteto, M., Cassinelli, G., Lanzi, C., Pisano, C., Ilan, N., Vlodavsky, I., and Zunino, F. (2011) Preclinical and clinical significance of heparanase in Ewing sarcoma. J. Cell. Mol. Med. 115, 1857-1864
7. Vreys, V., and David, G. (2007) Mammalian heparanase: What is the message? J. Cell Mol. Med. 11, 427-452 (Pubitemid 47153456)
8. Casu, B., Vlodavsky, I., and Sanderson, R. D. (2008) Non-anticoagulant heparins and inhibition of cancer. Pathophysiol. Haemost. Thromb. 36, 195-203
9. Dredge, K., Hammond, E., Davis, K., Li, C. P., Liu, L., Johnstone, K., Handley, P., Wimmer, N., Gonda, T. J., Gautam, A., Ferro, V., and Bytheway, I. (2010) The PG500 series: Novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest. New Drugs 28, 276-283
10. McKenzie, E. A. (2007) Heparanase: A target for drug discovery in cancer and inflammation. Br. J. Pharmacol. 151, 1-14
11. Miao, H. Q., Liu, H., Navarro, E., Kussie, P., and Zhu, Z. (2006) Development of heparanase inhibitors for anti-cancer therapy. Curr. Med. Chem. 13, 2101-2111 (Pubitemid 44132602)
12. Vlodavsky, I., Ilan, N., Naggi, A., and Casu, B. (2007) Heparanase: Structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr. Pharm. Des. 13, 2057-2073 (Pubitemid 47044735)
13. Levy-Adam, F., Ilan, N., and Vlodavsky, I. (2010) Tumorigenic and adhesive properties of heparanase. Semin. Cancer Biol. 20, 153-160
14. Lerner, I., Baraz, L., Pikarsky, E., Meirovitz, A., Edovitsky, E., Peretz, T., Vlodavsky, I., and Elkin, M. (2008) Function of heparanase in prostate tumorigenesis: Potential for therapy. Clin. Cancer Res. 14, 668-676 (Pubitemid 351231146)
15. Barash, U., Cohen-Kaplan, V., Dowek, I., Sanderson, R. D., Ilan, N., and Vlodavsky, I. (2010) Proteoglycans in health and disease: New concepts for heparanase function in tumor progression and metastasis. FEBS J. 277, 3890-3903
16. Okawa, T., Naomoto, Y., Nobuhisa, T., Takaoka, M., Motoki, T., Shirakawa, Y., Yamatsuji, T., Inoue, H., Ouchida, M., Gunduz, M., Nakajima, M., and Tanaka, N. (2005) Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2. Clin. Cancer Res. 11, 7995-8005 (Pubitemid 41698740)
17. Cohen-Kaplan, V., Naroditsky, I., Zetser, A., Ilan, N., Vlodavsky, I., and Doweck, I. (2008) Heparanase induces VEGF-C and facilitates tumor lymphangiogenesis. Int. J. Cancer 123, 2566-2573
18. Fux, L., Ilan, N., Sanderson, R. D., and Vlodavsky, I. (2009) Heparanase: Busy at the cell surface. Trends Biochem. Sci. 34, 511-519
19. Ramani, V. C., Yang, Y., Ren, Y., Nan, L., and Sanderson, R. D. (2011) Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J. Biol. Chem. 286, 6490-6499
20. Yang, Y., Ren, Y., Ramani, V. C., Nan, L., Suva, L. J., and Sanderson, R. D. (2010) Heparanase enhances local and systemic osteolysis in multiple myeloma by up-regulating the expression and secretion of RANKL. Cancer Res. 70, 8329-8338
21. Cohen-Kaplan, V., Doweck, I., Naroditsky, I., Vlodavsky, I., and Ilan, N. (2008) Heparanase augments epidermal growth factor receptor phosphorylation: Correlation with head and neck tumor progression. Cancer Res. 68, 10077-10085
22. Fux, L., Feibish, N., Cohen-Kaplan, V., Gingis-Velitski, S., Feld, S., Geffen, C., Vlodavsky, I., and Ilan, N. (2009) Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res. 69, 1758-1767
23. Zetser, A., Bashenko, Y., Edovitsky, E., Levy-Adam, F., Vlodavsky, I., and Ilan, N. (2006) Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and SRC activation. Cancer Res. 66, 1455-1463 (Pubitemid 43259926)
24. Gingis-Velitski, S., Zetser, A., Flugelman, M. Y., Vlodavsky, I., and Ilan, N. (2004) Heparanase induces endothelial cell migration via protein kinase B/AKT activation. J. Biol. Chem. 279, 23536-23541 (Pubitemid 38685666)
25. Barash, U., Cohen-Kaplan, V., Arvatz, G., Gingis-Velitski, S., Levy-Adam, F., Nativ, O., Shemesh, R., Ayalon-Sofer, M., Ilan, N., and Vlodavsky, I. (2010) A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics. Faseb J. 24, 1239-1248
26. Ben-Zaken, O., Gingis-Velitski, S., Vlodavsky, I., and Ilan, N. (2007) Heparanase induces AKT phosphorylation via a lipid raft receptor. Biochem. Biophys. Res. Commun. 361, 829-834 (Pubitemid 47259014)
27. Rosenthal, E. L., Kulbersh, B. D., Duncan, R. D., Zhang, W., Magnuson, J. S., Carroll, W. R., and Zinn, K. (2006) In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence. Laryngoscope 116, 1636-1641 (Pubitemid 44368086)
28. Weichselbaum, R. R., Dunphy, E. J., Beckett, M. A., Tybor, A. G., Moran, W. J., Goldman, M. E., Vokes, E. E., and Panje, W. R. (1989) Epidermal growth factor receptor gene amplification and expression in head and neck cancer cell lines. Head Neck 11, 437-442 (Pubitemid 19210525)
29. Nadav, L., Katz, B. Z., Baron, S., Cohen, N., Naparstek, E., and Geiger, B. (2006) The generation and regulation of functional diversity of malignant plasma cells. Cancer Res. 66, 8608-8616 (Pubitemid 44449175)
30. Levy-Adam, F., Feld, S., Suss-Toby, E., Vlodavsky, I., and Ilan, N. (2008) Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans. PLoS ONE 3, e2319
31. Zetser, A., Levy-Adam, F., Kaplan, V., Gingis-Velitski, S., Bashenko, Y., Schubert, S., Flugelman, M. Y., Vlodavsky, I., and Ilan, N. (2004) Processing and activation of latent heparanase occurs in lysosomes. J. Cell Sci. 117, 2249-2258 (Pubitemid 38807493)
32. Doweck, I., Kaplan-Cohen, V., Naroditsky, I., Sabo, E., Ilan, N., and Vlodavsky, I. (2006) Heparanase localization and expression by head and neck cancer: Correlation with tumor progression and patient survival. Neoplasia 8, 1055-1061 (Pubitemid 44936155)
33. Levy-Adam, F., Feld, S., Cohen-Kaplan, V., Shteingauz, A., Gross, M., Arvatz, G., Naroditsky, I., Ilan, N., Doweck, I., and Vlodavsky, I. (2010) Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J. Biol. Chem. 285, 28010-28019
34. Valgeirsdóttir, S., Ruusala, A., and Heldin, C. H. (1999) MEK is a negative regulator of Stat5b in PDGF-stimulated cells. FEBS Lett. 450, 1-7 (Pubitemid 29206701)
35. Frank, D. A. (2007) STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 251, 199-210
36. Reich, N. C., and Liu, L. (2006) Tracking STAT nuclear traffic. Nat. Rev. Immunol. 6, 602-612 (Pubitemid 44134093)
37. Yu, H., Pardoll, D., and Jove, R. (2009) STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 9, 798-809
38. Paukku, K., and Silvennoinen, O. (2004) STATs as critical mediators of signal transduction and transcription: Lessons learned from STAT5. Cytokine Growth Factor Rev. 15, 435-455 (Pubitemid 39550454)
39. Silver, D. L., Naora, H., Liu, J., Cheng, W., and Montell, D. J. (2004) Activated signal transducer and activator of transcription (STAT) 3: Localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res. 64, 3550-3558 (Pubitemid 38657931)
40. Atkinson, G. P., Nozell, S. E., and Benveniste, E. T. (2010) NF-κB and STAT3 signaling in glioma: Targets for future therapies. Expert Rev. Neurother. 10, 575-586
41. Pectasides, E., Egloff, A. M., Sasaki, C., Kountourakis, P., Burtness, B., Fountzilas, G., Dafni, U., Zaramboukas, T., Rampias, T., Rimm, D., Grandis, J., and Psyrri, A. (2010) Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clin. Cancer Res. 16, 2427-2434
42. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., and Thun, M. J. (2009) Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249
43. Fung, C., and Grandis, J. R. (2010) Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin. Emerg. Drugs 15, 355-373
44. Lai, S. Y., and Johnson, F. M. (2010) Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches. Drug Resist. Updat. 13, 67-78
45. Leeman, R. J., Lui, V. W., and Grandis, J. R. (2006) STAT3 as a therapeutic target in head and neck cancer. Expert Opin. Biol. Ther. 6, 231-241 (Pubitemid 43344743)
46. Song, J. I., and Grandis, J. R. (2000) STAT signaling in head and neck cancer. Oncogene 19, 2489-2495 (Pubitemid 30339204)
47. Seethala, R. R., Gooding, W. E., Handler, P. N., Collins, B., Zhang, Q., Siegfried, J. M., and Grandis, J. R. (2008) Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes. Clin. Cancer Res. 14, 1303-1309 (Pubitemid 351413908)
48. Germain, D., and Frank, D. A. (2007) Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin. Cancer Res. 13, 5665-5669 (Pubitemid 47583890)
49. Sehgal, P. B. (2008) Paradigm shifts in the cell biology of STAT signaling. Semin Cell Dev. Biol. 19, 329-340
50. Schlessinger, K., and Levy, D. E. (2005) Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res. 65, 5828-5834 (Pubitemid 40911187)
51. Chen, Z., and Han, Z. C. (2008) STAT3: A critical transcription activator in angiogenesis. Med. Res. Rev. 28, 185-200 (Pubitemid 351281185)
52. Lerner, I., Hermano, E., Zcharia, E., Rodkin, D., Bulvik, R., Doviner, V., Rubinstein, A. M., Ishai-Michaeli, R., Atzmon, R., Sherman, Y., Meirovitz, A., Peretz, T., Vlodavsky, I., and Elkin, M. (2011) Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J. Clin. Invest. 121, 1709-1721
53. Yu, H., and Jove, R. (2004) The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 4, 97-105 (Pubitemid 38198738)
54. Li, H., Zhang, Y., Glass, A., Zellweger, T., Gehan, E., Bubendorf, L., Gelmann, E. P., and Nevalainen, M. T. (2005) Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin. Cancer Res. 11, 5863-5868 (Pubitemid 41170314)
55. Xi, S., Zhang, Q., Gooding, W. E., Smithgall, T. E., and Grandis, J. R. (2003) Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res. 63, 6763-6771 (Pubitemid 37322957)
56. Koppikar, P., Lui, V. W., Man, D., Xi, S., Chai, R. L., Nelson, E., Tobey, A. B., and Grandis, J. R. (2008) Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelialmesenchymal transition, and resistance to epidermal growth factor receptor targeting. Clin. Cancer Res. 14, 7682-7690